Altimmune Inc
(FRA:3G0)
€
6.001
0.133 (2.27%)
Market Cap: 403.43 Mil
Enterprise Value: 234.43 Mil
PE Ratio: 0
PB Ratio: 2.51
GF Score: 41/100 Altimmune Inc (FRA:3G0) Transcripts
- Q4 2023 Altimmune Inc Earnings Call TranscriptMar 27, 2024€8.28 (+4.18%)Earnings
- Altimmune Inc Conference Call TranscriptDec 01, 2023
- Q3 2023 Altimmune Inc Earnings Call TranscriptNov 07, 2023€2.51 (-0.12%)Earnings
- Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Altimmune Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Altimmune Inc Earnings Call TranscriptAug 10, 2023€2.72 (+0.55%)Earnings
- Altimmune Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Altimmune Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Altimmune Inc Earnings Call TranscriptMay 11, 2023€4.46 (-1.20%)Earnings
- Altimmune Inc Conference Call TranscriptMar 21, 2023
- Q4 2022 Altimmune Inc Earnings Call TranscriptFeb 28, 2023Earnings
- Altimmune Inc Topline Results of Pemvidutide in Subjects with NAFLD Call TranscriptDec 20, 2022
- Altimmune Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Altimmune Inc Earnings Call TranscriptNov 10, 2022€10.33 (+9.52%)Earnings
- Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference TranscriptOct 18, 2022
- Altimmune Inc Conference Call TranscriptSep 14, 2022
- Q2 2022 Altimmune Inc Earnings Call TranscriptAug 11, 2022€12.17 (+2.53%)Earnings
- Altimmune Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Altimmune Inc Earnings Call TranscriptMay 12, 2022€3.68 (-7.68%)Earnings
- Q4 2021 Altimmune Inc Earnings Call TranscriptMar 15, 2022€5.27 (-10.50%)Earnings
- Q3 2021 Altimmune Inc Earnings Call TranscriptNov 10, 2021€9.23 (-0.28%)Earnings
- Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call TranscriptSep 30, 2021
- Altimmune Inc to Discuss the 12-Week Data from Phase 1 Clinical Trial of ALT-801 - Conference Call TranscriptSep 28, 2021
- Q2 2021 Altimmune Inc Earnings Call TranscriptAug 11, 2021€9.09 (+3.86%)Earnings
- Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call TranscriptJun 16, 2021
- Q1 2021 Altimmune Inc Earnings Call TranscriptMay 17, 2021€10.58 (-0.80%)Earnings
- Altimmune Inc to Present AdCOVIDâ„¢ intranasal COVID-19 at the World Vaccine Congress TranscriptMay 04, 2021
- Q4 2020 Altimmune Inc Earnings Call TranscriptFeb 25, 2021€17.22 (+4.05%)Earnings
- Q3 2020 Altimmune Inc Earnings Call TranscriptNov 10, 2020€7.82 (+10.51%)Earnings
- Altimmune Inc Annual Shareholders Meeting TranscriptSep 24, 2020
- Q2 2020 Altimmune Inc Earnings Call TranscriptAug 12, 2020€19.76 (-0.85%)Earnings
- Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call TranscriptJun 01, 2020
- Q1 2020 Altimmune Inc Earnings Call TranscriptMay 14, 2020€4.54 (+35.87%)Earnings
- Q4 2019 Altimmune Inc Earnings Call TranscriptMar 27, 2020€2.43 (-23.56%)Earnings
- Q2 2019 Altimmune Inc Earnings Call TranscriptAug 14, 2019€1.87 (-2.60%)Earnings
- 1